Loading
A phase 3 trial of Durvalumab, Tremelimumab, Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). is a phase 3 interventional study registered as NCT03164616 by AstraZeneca, with 1186 participants enrolled, started 2017-06-01 and due to reach its primary completion in 2021-03-12. Interventions recorded: Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin. Conditions listed: Non Small Cell Lung Cancer NSCLC. Results were posted on ClinicalTrials.gov in 2022; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
1,186 enrolled.
95% CI 4.7 to 6.5; Figures from the ClinicalTrials.gov results section (first posted 2022-04-07), not from a publication · 95% CI 4.6 to 5.8
Source95% CI 11.4 to 14.7; Figures from the ClinicalTrials.gov results section (first posted 2022-04-07), not from a publication · 95% CI 10.5 to 13.1
SourceFigures from the ClinicalTrials.gov results section (first posted 2022-04-07), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS); D + SoC Compared With SoC Aloneprimary | D + SoC | 338 | 5.5 months | 0.74 (0.62 to 0.885) | 0.00093 | link |
| SoC Alone | 337 | 4.8 months | ||||
| Overall Survival (OS); D + SoC Compared With SoC Aloneprimary | D + SoC | 338 | 13.3 months | 0.86 (0.724 to 1.016) | 0.07581 | link |
| SoC Alone | 337 | 11.7 months | ||||
| Objective Response Rate (ORR) | T + D + SoC | 335 | 46.3% | - | - | link |
| D + SoC | 330 | 48.5% | ||||
| SoC Alone | 332 | 33.4% |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tremelimumab, Durvalumab, Gemcitabine, AstraZeneca.
Shares Tremelimumab, Durvalumab, Gemcitabine, AstraZeneca.
Shares Tremelimumab, Durvalumab, AstraZeneca, Cisplatin.
Shares Durvalumab, Paclitaxel / nab-paclitaxel, Gemcitabine, AstraZeneca.
Shares Durvalumab, Paclitaxel / nab-paclitaxel, Gemcitabine, AstraZeneca.
Shares Tremelimumab, Durvalumab, Paclitaxel / nab-paclitaxel, AstraZeneca.
Shares Durvalumab, AstraZeneca, Cisplatin, Carboplatin.
Shares Tremelimumab, Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/